Compare Cytokinetics Inc (CYTK) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Southwest Airlines Co — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Southwest Airlines Co trades at $40.89 (market cap $20.23B). The key difference: Southwest Airlines Co is far larger — about 2.3× Cytokinetics Inc's market cap, and Southwest Airlines Co pays a 1.74% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Southwest Airlines Co for 65 Days on average.
| CYTK | LUV | |
|---|---|---|
Market Cap | $8.62B | $20.23B |
Volume | 2,594,626 | 14,560,422 |
Sector | Health | Industrials |
52-Week High | $87.26 | $54.80 |
52-Week Low | $54.76 | $29.67 |
Typical Hold Time | 19 Days | 65 Days |
Enterprise Value | $8.72B | $23.33B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q2 2026 EPS beating expectations at $0.94 versus $0.51 expected, while revenue growth continues from $28.06B in 2025 to projected $30.1B in 2026. Recent corporate developments include upcoming Q3 2026 earnings release on October 21 and successful commercial transformation initiatives driving revenue growth.
LUV presents a compelling value opportunity with attractive valuation metrics (P/S 0.72, EV/EBITDA 8.4) and analyst consensus target of $49.61 offering 19% upside. However, investors face risks from volatile fuel costs, competitive pressures in the airline industry, and inconsistent earnings performance as seen in the Q1 2026 miss. The stock's transformation into a merchandised airline with new revenue streams provides growth catalysts but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
